Duearity AB (publ) (DEAR.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -24.77 Million SEK | -30.79% |
| 2022 | -19.01 Million SEK | -23.73% |
| 2021 | -80 Thousand SEK | -1059.21% |
| 2020 | -1.32 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.69 Million SEK | 27.72% |
| 2024 Q1 | -6.5 Million SEK | 47.38% |
| 2023 FY | - SEK | -30.79% |
| 2023 Q2 | -6.07 Million SEK | -73.8% |
| 2023 Q1 | -3.49 Million SEK | 16.3% |
| 2023 Q4 | -7.54 Million SEK | 2.13% |
| 2023 Q3 | -7.7 Million SEK | -26.83% |
| 2022 Q4 | -4.17 Million SEK | -5.51% |
| 2022 FY | - SEK | -23.73% |
| 2022 Q1 | -5.59 Million SEK | -20.89% |
| 2022 Q3 | -3.95 Million SEK | 26.98% |
| 2022 Q2 | -5.42 Million SEK | 3.16% |
| 2021 Q3 | -3.92 Million SEK | 6.15% |
| 2021 FY | - SEK | -1059.21% |
| 2021 Q4 | -4.63 Million SEK | -18.09% |
| 2021 Q1 | -2.62 Million SEK | 0.0% |
| 2021 Q2 | -4.17 Million SEK | -59.08% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q3 | -224 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 67.87% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 106.016% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 106.016% |
| Arcoma AB | 6.24 Million SEK | 496.591% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 72.462% |
| BICO Group AB (publ) | 322.3 Million SEK | 107.688% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 137.556% |
| CellaVision AB (publ) | 207.24 Million SEK | 111.956% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 63.777% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 11.323% |
| C-Rad AB (publ) | 48.9 Million SEK | 150.669% |
| Dignitana AB (publ) | -264 Thousand SEK | -9285.985% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 71.746% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.418% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 63.154% |
| Iconovo AB (publ) | -35.33 Million SEK | 29.875% |
| Integrum AB (publ) | 8.76 Million SEK | 382.816% |
| Luxbright AB (publ) | -23.86 Million SEK | -3.822% |
| Mentice AB (publ) | 28.87 Million SEK | 185.821% |
| OssDsign AB (publ) | -122.02 Million SEK | 79.693% |
| Paxman AB (publ) | 31.22 Million SEK | 179.346% |
| Promimic AB (publ) | -3.68 Million SEK | -572.611% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 83.536% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 52.191% |
| ScandiDos AB (publ) | -13.35 Million SEK | -85.527% |
| Sectra AB (publ) | 615.06 Million SEK | 104.029% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 52.047% |
| Senzime AB (publ) | -118.82 Million SEK | 79.146% |
| SpectraCure AB (publ) | -20.96 Million SEK | -18.17% |
| Stille AB | 56.04 Million SEK | 144.216% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.222% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 119.577% |